It’s an appealing income play to consider Predictive Oncology Inc. (POAI)

After finishing at $0.31 in the prior trading day, Predictive Oncology Inc. (NASDAQ: POAI) closed at $0.31, up 1.99%. In other words, the price has increased by $+0.0061 from its previous closing price. On the day, 117235 shares were traded. POAI stock price reached its highest trading level at $0.3200 during the session, while it also had its lowest trading level at $0.3071.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.



Our goal is to gain a better understanding of POAI by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.60 and its Current Ratio is at 7.70. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 26 when HANDLEY DANIEL E bought 2,550 shares for $0.37 per share. The transaction valued at 955 led to the insider holds 49,666 shares of the business.

HANDLEY DANIEL E bought 2,800 shares of POAI for $980 on May 25. The Director now owns 47,116 shares after completing the transaction at $0.35 per share. On May 24, another insider, ENGLE J MELVILLE, who serves as the Director of the company, bought 159,500 shares for $0.37 each. As a result, the insider paid 59,334 and bolstered with 203,393 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 15.72 while its Price-to-Book (P/B) ratio in mrq is 0.82.

Stock Price History:

Over the past 52 weeks, POAI has reached a high of $1.10, while it has fallen to a 52-week low of $0.21. The 50-Day Moving Average of the stock is 0.3119, while the 200-Day Moving Average is calculated to be 0.5240.

Shares Statistics:

The stock has traded on average 272.78K shares per day over the past 3-months and 285.46k shares per day over the last 10 days, according to various share statistics. A total of 78.38M shares are outstanding, with a floating share count of 75.52M. Insiders hold about 1.70% of the company’s shares, while institutions hold 5.70% stake in the company. Shares short for POAI as of Oct 13, 2022 were 133.22k with a Short Ratio of 0.20M, compared to 185.06k on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 0.17% and a Short% of Float of 0.17%.

Earnings Estimates

Its stock is currently analyzed by 0 different market analysts. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0 and a low estimate of $0, while EPS last year was -$0.05. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.

Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.

Revenue Estimates

1 analysts predict $2M in revenue for the current quarter. It ranges from a high estimate of $2M to a low estimate of $2M. As of the current estimate, Predictive Oncology Inc.’s year-ago sales were $600k, an estimated increase of 233.30% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $4M, an increase of 1,173.90% over than the figure of $233.30% in the same quarter last year. There is a high estimate of $4M for the next quarter, whereas the lowest estimate is $4M.

A total of 1 analysts have provided revenue estimates for POAI’s current fiscal year. The highest revenue estimate was $12M, while the lowest revenue estimate was $12M, resulting in an average revenue estimate of $12M. In the same quarter a year ago, actual revenue was $1.42M, up 745.10% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $33.6M in the next fiscal year. The high estimate is $33.6M and the low estimate is $33.6M. The average revenue growth estimate for next year is up 180.00% from the average revenue estimate for this year.